SAN FRANCISCO--(BUSINESS WIRE)--The Institute for Systems Biology (ISB) of Seattle, WA, is collaborating with the Gladstone Institute of Neurological Disease (GIND) and its Taube-Koret Center for Huntington’s Disease Research to use whole-genome sequencing to identify genes and novel drug targets related to the onset and progression of Huntington’s disease (HD). The research team, led by GIND associate director and senior investigator Steven Finkbeiner, M.D., Ph.D., will also use induced pluripotent stem (iPS) cells from patients with HD to screen for drugs that might delay, prevent, or even reverse this devastating condition.
